{"id":"W2139672588","doi":"10.1111/j.1600-6143.2012.04127.x","title":"Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year","year":2012,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Yonsei University College of Medicine; Baylor University Medical Center; Cilag; Astellas Pharma; Seoul National University Hospital; Seoul National University; Yonsei University; University of South Carolina; University of Arkansas for Medical Sciences; Amgen; Baylor University; Universidade de Coimbra; Yale University; Erasmus Medisch Centrum; Cedars-Sinai Medical Center; Northwestern University; Pfizer; Feinberg School of Medicine; University of Alberta; Bristol-Myers Squibb","keywords":"Medicine; Basiliximab; Tofacitinib; Janus kinase inhibitor; Internal medicine; Renal function; Gastroenterology; Urology; Transplantation; Chronic allograft nephropathy; Kidney transplantation; Mycophenolic acid; Neutropenia; Surgery; Chemotherapy; Rheumatoid arthritis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006843895,0.000184678,0.0008232573,0.0002825336,0.00004211956,0.000007170908,0.00004802655,0.00005914387,0.00008920653],"category_scores_gemma":[0.0000504981,0.0001390766,0.0002561586,0.0002055295,0.0001661117,0.0002242605,0.000002079136,0.000174037,0.000002583861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009303192,"about_ca_system_score_gemma":0.00009533985,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005376793,"about_ca_topic_score_gemma":0.000007028018,"domain_scores_codex":[0.9979731,0.0002874943,0.0009668883,0.0001284177,0.0003928345,0.0002512792],"domain_scores_gemma":[0.9985641,0.0003688989,0.0005740138,0.00008401352,0.00009697623,0.0003119835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8836352,0.001292416,0.1044047,0.0001795925,0.0004086642,0.00004387385,0.002544439,0.00002370265,0.002433127,0.00006459541,0.000004422844,0.004965247],"study_design_scores_gemma":[0.8705478,0.003129796,0.1200976,0.0007691659,0.001711745,0.0003948852,0.0001170466,0.00001684516,0.002986594,0.00001741212,0.00007676127,0.0001343717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926918,0.00006572609,0.005810654,0.0001585117,0.0002003399,0.0006149616,0.0002521834,0.000008162228,0.0001976724],"genre_scores_gemma":[0.9959423,0.002037836,0.001356569,0.0001597816,0.0000952412,0.000009550906,0.0003599139,0.00001846643,0.00002035218],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01569292,"threshold_uncertainty_score":0.5671381,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01422037986658146,"score_gpt":0.296094047945285,"score_spread":0.2818736680787035,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}